Skip to main content

Breast Cancer

Breast Cancer, CDK4/6 Inhibitors, Radiation Therapy

Favorable Tolerability Profile of Sequential Radiation Therapy in Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer

Breast Cancer

Expanded Safety Analysis of the Phase 3b CompLEEment-1 Trial with Ribociclib plus Letrozole in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer, CDK4/6 Inhibitors

A Network Meta-Analysis of Treatment-Related Adverse Events of Various CDK4/6 Inhibitors in Metastatic Breast Cancer

Breast Cancer

Maintenance Therapy with Everolimus plus Aromatase Inhibitors in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Updated Analyses of the Phase 3 Randomized MAIN-A Trial

Breast Cancer

Patients with Metastatic Breast Cancer and the Use of Chemotherapy During End of Life

Breast Cancer

In a Real-World Setting, the RIBANNA Study Showed Diverse Population Characteristics Among Patients Who Received Ribociclib Treatment

Breast Cancer, CDK4/6 Inhibitors

Retrospectively Analyzing the Use of CDK4/6 Inhibitors to Treat Adult Female Patients with Metastatic Breast Cancer

Breast Cancer

Efficacy Outcomes of Platinum-Based Chemotherapy in Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Case Reports, Breast Cancer, Infusion Issues

Desensitization Permits Continued Trastuzumab and Ado-Trastuzumab Emtansine Therapy After Hypersensitivity Reaction

Anna Kempke, PharmD, BCOP, BCPS, Shawna Kraft, PharmD, BCOP, Mariana Castells, MD, PhD, Rajan Ravikumar, MD, Catherine Van Poznak, MD

Anna Kempke, PharmD, BCOP, BCPS; Shawna Kraft, PharmD, BCOP; Mariana Castells, MD, PhD; Rajan Ravikumar, MD; Catherine Van Poznak, MD

FDA Updates, Breast Cancer

Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple‑Negative Breast Cancer

6
7
8
9
10
11
12

Page 9 of 12
Results 81 - 90 of 114